![]() ![]() The researchers plan to continue observation for 180 days for long-term safety evaluation of the patch. The figures highly exceeded FDA's influenza vaccine permission standard set in 2007. The trial was on healthy adults aged 18 to 39, evaluating the drug's safety, response, tolerance, and immunogenicity compared to the placebo group.įifty-seven days after the vaccination, the antibody-positive rates of the two doses (15ug/7.5ug) were 85 percent and 77 percent, respectively, and the antibody protection rates were 92 percent. It controls the drug delivery speed and time properly with a microneedle that can slowly inject the drug from the patch with little pain. MIMIX-Flu is a device that combines GC's influenza vaccine antigen with Vaxess's patch-based subcutaneous drug delivery technology. ![]() GC Corporation announced on Thursday the positive results of a study on its patch-type influenza vaccine, being co-developed with Vaxess Technologies. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |